Article Versions
Related Info
More by Authors
Share This Article
  •  CiteULike
  •  Facebook
  •  Mendeley
  •  Twitter
  • More services
Cancers 2013, 5(3), 919-942; doi:10.3390/cancers5030919
Review

Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies

1email, 2email, 2email, 3email, 3email and 1,* email
Received: 22 April 2013; in revised form: 3 July 2013 / Accepted: 12 July 2013 / Published: 25 July 2013
(This article belongs to the Special Issue Cancer Epigenetics)
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: Hydroxamate-based histone deacetylase inhibitors (Hb-HDACIs), such as vorinostat, belinostat and panobinostat, have been previously shown to have a wide range of activity in hematologic malignancies such as cutaneous T-cell lymphoma and multiple myeloma. Recent data show that they synergize with a variety of cytotoxic and molecular targeted agents in many different solid tumors, including breast, prostate, pancreatic, lung and ovarian cancer. Hb-HDACIs have a quite good toxicity profile and are now being tested in phase I and II clinical trials in solid tumors with promising results in selected neoplasms, such as hepatocarcinoma. This review will focus on their clinical activity and safety in patients with advanced solid neoplasms.
Keywords: hydroxamate-based histone deacetylase inhibitors; histone deacetylase inhibitors; vorinostat; belinostat; panobinostat; pracinostat; abexinostat; resminostat
PDF Full-text Download PDF Full-Text [371 KB, uploaded 25 July 2013 09:37 CEST]

Export to BibTeX |
EndNote


MDPI and ACS Style

Grassadonia, A.; Cioffi, P.; Simiele, F.; Iezzi, L.; Zilli, M.; Natoli, C. Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies. Cancers 2013, 5, 919-942.

AMA Style

Grassadonia A, Cioffi P, Simiele F, Iezzi L, Zilli M, Natoli C. Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies. Cancers. 2013; 5(3):919-942.

Chicago/Turabian Style

Grassadonia, Antonino; Cioffi, Pasquale; Simiele, Felice; Iezzi, Laura; Zilli, Marinella; Natoli, Clara. 2013. "Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies." Cancers 5, no. 3: 919-942.

Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert